These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 24448819)

  • 1. Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells.
    Eritja N; Domingo M; Dosil MA; Mirantes C; Santacana M; Valls J; Llombart-Cussac A; Matias-Guiu X; Dolcet X
    Mol Cancer Ther; 2014 Apr; 13(4):776-87. PubMed ID: 24448819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
    Konecny GE; Kolarova T; O'Brien NA; Winterhoff B; Yang G; Qi J; Qi Z; Venkatesan N; Ayala R; Luo T; Finn RS; Kristof J; Galderisi C; Porta DG; Anderson L; Shi MM; Yovine A; Slamon DJ
    Mol Cancer Ther; 2013 May; 12(5):632-42. PubMed ID: 23443805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
    André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
    Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.
    Konecny GE; Finkler N; Garcia AA; Lorusso D; Lee PS; Rocconi RP; Fong PC; Squires M; Mishra K; Upalawanna A; Wang Y; Kristeleit R
    Lancet Oncol; 2015 Jun; 16(6):686-94. PubMed ID: 25981814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.
    Byron SA; Chen H; Wortmann A; Loch D; Gartside MG; Dehkhoda F; Blais SP; Neubert TA; Mohammadi M; Pollock PM
    Neoplasia; 2013 Aug; 15(8):975-88. PubMed ID: 23908597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
    Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
    Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.
    Wang Y; Ding X; Wang S; Moser CD; Shaleh HM; Mohamed EA; Chaiteerakij R; Allotey LK; Chen G; Miyabe K; McNulty MS; Ndzengue A; Barr Fritcher EG; Knudson RA; Greipp PT; Clark KJ; Torbenson MS; Kipp BR; Zhou J; Barrett MT; Gustafson MP; Alberts SR; Borad MJ; Roberts LR
    Cancer Lett; 2016 Sep; 380(1):163-73. PubMed ID: 27216979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations.
    Kim DH; Kwak Y; Kim ND; Sim T
    Cancer Biol Ther; 2016; 17(1):65-78. PubMed ID: 26574622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2
    Packer LM; Geng X; Bonazzi VF; Ju RJ; Mahon CE; Cummings MC; Stephenson SA; Pollock PM
    Mol Cancer Ther; 2017 Apr; 16(4):637-648. PubMed ID: 28119489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor Effects and Mechanisms of AZD4547 on FGFR2-Deregulated Endometrial Cancer Cells.
    Kwak Y; Cho H; Hur W; Sim T
    Mol Cancer Ther; 2015 Oct; 14(10):2292-302. PubMed ID: 26294741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma.
    Huynh H; Chow PK; Tai WM; Choo SP; Chung AY; Ong HS; Soo KC; Ong R; Linnartz R; Shi MM
    J Hepatol; 2012 Mar; 56(3):595-601. PubMed ID: 22027573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR
    Musolino A; Campone M; Neven P; Denduluri N; Barrios CH; Cortes J; Blackwell K; Soliman H; Kahan Z; Bonnefoi H; Squires M; Zhang Y; Deudon S; Shi MM; André F
    Breast Cancer Res; 2017 Feb; 19(1):18. PubMed ID: 28183331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endometrial Cancers Harboring Mutated Fibroblast Growth Factor Receptor 2 Protein Are Successfully Treated With a New Small Tyrosine Kinase Inhibitor in an Orthotopic Mouse Model.
    Taurin S; Yang CH; Reyes M; Cho S; Coombs DM; Jarboe EA; Werner TL; Peterson CM; Janát-Amsbury MM
    Int J Gynecol Cancer; 2018 Jan; 28(1):152-160. PubMed ID: 28953502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.
    Chen ZY; Shi M; Peng LX; Wei W; Li XJ; Guo ZX; Li SH; Zhong C; Qian CN; Guo RP
    J Transl Med; 2012 Dec; 10():245. PubMed ID: 23228017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.
    Byron SA; Loch DC; Pollock PM
    Int J Gynecol Cancer; 2012 Nov; 22(9):1517-26. PubMed ID: 23060048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma.
    Kang CW; Jang KW; Sohn J; Kim SM; Pyo KH; Kim H; Yun MR; Kang HN; Kim HR; Lim SM; Moon YW; Paik S; Kim DJ; Kim JH; Cho BC
    Mol Cancer Ther; 2015 Oct; 14(10):2238-48. PubMed ID: 26208525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line dovitinib in metastatic endometrial cancer.
    Block MS; Dowdy SC
    Lancet Oncol; 2015 Jun; 16(6):604-6. PubMed ID: 25981815
    [No Abstract]   [Full Text] [Related]  

  • 18. Antitumoral effects of dovitinib in triple-negative breast cancer are synergized by calcitriol in vivo and in vitro.
    García-Quiroz J; Cárdenas-Ochoa N; García-Becerra R; Morales-Guadarrama G; Méndez-Pérez EA; Santos-Cuevas C; Ramírez-Nava GJ; Segovia-Mendoza M; Prado-García H; Avila E; Larrea F; Díaz L
    J Steroid Biochem Mol Biol; 2021 Nov; 214():105979. PubMed ID: 34438041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced FGFR signalling predisposes pancreatic cancer to the effect of a potent FGFR inhibitor in preclinical models.
    Zhang H; Hylander BL; LeVea C; Repasky EA; Straubinger RM; Adjei AA; Ma WW
    Br J Cancer; 2014 Jan; 110(2):320-9. PubMed ID: 24327018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.
    Wan X; Corn PG; Yang J; Palanisamy N; Starbuck MW; Efstathiou E; Li Ning Tapia EM; Zurita AJ; Aparicio A; Ravoori MK; Vazquez ES; Robinson DR; Wu YM; Cao X; Iyer MK; McKeehan W; Kundra V; Wang F; Troncoso P; Chinnaiyan AM; Logothetis CJ; Navone NM
    Sci Transl Med; 2014 Sep; 6(252):252ra122. PubMed ID: 25186177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.